

**See page 880/1 : where you'll find the evidence confirmed that Zantac (ranitidine) can help you to reduce duodenal ulcer relapse rates.**

**Contributors**

Glaxo Laboratories

**Publication/Creation**

[1984?]

**Persistent URL**


<https://wellcomecollection.org/works/jyap6cj7>

**License and attribution**

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection  
183 Euston Road  
London NW1 2BE UK  
T +44 (0)20 7611 8722  
E [library@wellcomecollection.org](mailto:library@wellcomecollection.org)  
<https://wellcomecollection.org>



**See page 880/1**

**Where you'll find the evidence confirmed that Zantac (ranitidine) can help you to reduce duodenal ulcer relapse rates.**

## **PRESCRIBING INFORMATION:**

**DOSAGE AND ADMINISTRATION:** THE USUAL ADULT DOSE IS ONE 150mg TABLET TWICE DAILY OR A SINGLE DOSE OF 300mg AT NIGHT TIME FOR DUODENAL ULCER. IT IS NOT NECESSARY TO TIME THE DOSE IN RELATION TO MEALS. IN MOST CASES OF DUODENAL ULCER AND BENIGN GASTRIC ULCER, HEALING WILL OCCUR IN FOUR WEEKS. PATIENTS WITH A HISTORY OF RECURRENT ULCER MAY HAVE AN EXTENDED COURSE OF ONE 150mg TABLET DAILY AT BEDTIME. FOR REFLUX OESOPHAGITIS THE RECOMMENDED COURSE FOR ADULTS IS ONE 150mg TABLET TWICE DAILY FOR UP TO EIGHT WEEKS. **SIDE EFFECTS:** HEADACHES, DIZZINESS AND SKIN RASHES HAVE BEEN REPORTED. ANAPHYLACTOID REACTIONS HAVE BEEN SEEN RARELY. **PRECAUTIONS:** WHERE GASTRIC ULCER IS SUSPECTED, THE POSSIBILITY OF MALIGNANCY SHOULD BE EXCLUDED BEFORE THERAPY IS INSTITUTED. PATIENTS RECEIVING PROLONGED TREATMENT SHOULD BE EXAMINED PERIODICALLY. DOSAGE SHOULD BE REDUCED IN THE PRESENCE OF SEVERE RENAL IMPAIRMENT (SEE DATA SHEET). AS WITH ALL DRUGS, ZANTAC SHOULD BE USED DURING PREGNANCY AND NURSING ONLY IF STRICTLY NECESSARY. **CONTRA-INDICATIONS:** THERE ARE NO KNOWN CONTRA-INDICATIONS TO THE USE OF ZANTAC. **BASIC NHS COST:** (EXCLUSIVE OF VAT) 60 x 150mg TABLETS £27.43. 30 x 300mg TABLETS £27.43. **PRODUCT LICENCE NUMBERS:** 4/0279 (150mg), 4/0302 (300mg). ZANTAC IS A GLAXO TRADE MARK. FURTHER INFORMATION IS AVAILABLE ON REQUEST FROM: GLAXO LABORATORIES LIMITED, GREENFORD, MIDDLESEX UB6 0HE.

**Glaxo**

HOSPITAL UPDATE: 10, (11): Nov 1984